Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms (TADE)
This study has been completed.
Study NCT01075802   Information provided by Western Sydney Local Health District

First Received on February 24, 2010.   Last Updated on May 3, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
CYP2D6 Polymorphism
Additional conditions recognized in this trial
Breast Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
Tamoxifen
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Bone Density Conservation Agents
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Selective Estrogen Receptor Modulators
Therapeutic Uses
Sponsors listed in this trial
Western Sydney Local Health District
St George Hospital, Australia


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services